CDMOs Expand Peptide Offerings

January 22, 2019
Article > CDMOs Expand Capacity to Support Recent Market Trends

Article > CDMOs Expand Capacity to Support Recent Market Trends

By Dr. Matthieu Giraud, Director, Global Peptides, Lipids & Carbohydrates Platforms

Speciality Chemicals Magazine, February 2019


Dr Matthieu Giraud, Global Director of the Peptides, Lipids & Carbohydrates Platform at CordenPharma, elaborates on the expansion of peptide offerings to support recent trends in the global peptide market.

The early peptides were hormones, but peptides are now being developed for almost every therapeutic category ranging from anti-inflammatory to cancer. This and the growing number of therapeutic peptides in clinical trials are the key drivers for capacity expansion by leading contract development and manufacturing organisations (CDMOs) in the global peptide API market. CDMOs are focusing on internal and external capacity expansion and integration into the pharma supply chain, which ultimately boosts manufacturing activities for peptide APIs across the globe.

The global peptide API market was estimated to be valued at $1.7 billion in 2018 and is forecast to expand at a compound annual growth rate (CAGR) of 7.7% to reach $2.9 billion by 2025. North America clearly dominated the global market with a 48.2% value share. This region represents the highest growth incremental opportunity by 2025, of $576.9 million.

In terms of value, the European market, which accounted for 28.6% of the market in 2018, is expected to expand at the highest CAGR, 8.1%. However, in terms of volume, the Asia-Pacific market is expected to witness the highest CAGR of 10.2%. This region accounted for 16.5% of the world market in 2018, with Latin America (4.2%) and the rest of the world (2.5%) taking up the rest.

The US and Europe had over 57% of the global clinical trials for therapeutic peptides being carried out in them in 2017. This represents a market with huge growth potential. Multiple clinical studies in over 57 companies are under way across the two regions.

In the 1980s, nearly all peptides entering clinical development – such as Oxytocin, Leuprolin and Octreotide – were fewer than ten amino acids long. Average peptide length has increased (Figure 2) with each subsequent decade, largely due to improvements in peptide synthesis and manufacturing technology. The availability of a broader range of popular molecular targets, including B class G-protein coupled receptors that are activated by larger peptide ligands, has also played a role.

Read the Article Here